Dayna R Cenin1, Jill Tinmouth2, Steffie K Naber3, Catherine Dubé4, Bronwen R McCurdy5, Lawrence Paszat6, Linda Rabeneck2, Iris Lansdorp-Vogelaar3. 1. Department of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands; Centre for Health Services Research, School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia. Electronic address: d.cenin@erasmusmc.nl. 2. Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Ontario, Canada; Cancer Care Ontario, Toronto, Ontario, Canada. 3. Department of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands. 4. Cancer Care Ontario, Toronto, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. 5. Cancer Care Ontario, Toronto, Ontario, Canada. 6. Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Ontario, Canada.
Abstract
BACKGROUND & AIMS: Routine screening for colorectal cancer typically is recommended until age 74 years. Although it has been proposed that a screening stop age could be determined based on sex and comorbidity, less is known about the impact of screening history. We investigated the effects of screening history on the selection of an optimal age to stop screening. METHODS: We used the Microsimulation Screening Analysis-Colon model to estimate the harms and benefits of screening with biennial fecal immunochemical tests by sex, comorbidity status, and screening history. The optimal screening stop age was determined based on the incremental number needed for 1 additional life-year per 1000 screened individuals compared with the threshold provided by stopping screening at 76 years in the average-health population with a perfect screening history (attended all required screening, diagnostic, and follow-up tests) to biennial fecal immunochemical testing from age 50 years. RESULTS: For persons age 76 years, 157 women and 108 men with a perfect screening history would need to be screened to gain 1 life-year per 1000 screened individuals. Previously unscreened women with no comorbid conditions and no history of screening could undergo an initial screening through 90 years, whereas unscreened men could undergo initial screening through 88 years, before this balance is reached. As screening adherence improved or as comorbidities increased, the optimal age to stop screening decreased to a point that, regardless of sex, individuals with severe comorbidities and a perfect screening history should stop screening at age 66 years or younger. CONCLUSIONS: Based on the harm-benefit balance, the optimal stop age for colorectal cancer screening ranges from 66 years for unhealthy individuals with a perfect screening history to 90 years for healthy individuals without prior screening. These findings can be used to assist patients and clinicians in making decisions about screening participation.
BACKGROUND & AIMS: Routine screening for colorectal cancer typically is recommended until age 74 years. Although it has been proposed that a screening stop age could be determined based on sex and comorbidity, less is known about the impact of screening history. We investigated the effects of screening history on the selection of an optimal age to stop screening. METHODS: We used the Microsimulation Screening Analysis-Colon model to estimate the harms and benefits of screening with biennial fecal immunochemical tests by sex, comorbidity status, and screening history. The optimal screening stop age was determined based on the incremental number needed for 1 additional life-year per 1000 screened individuals compared with the threshold provided by stopping screening at 76 years in the average-health population with a perfect screening history (attended all required screening, diagnostic, and follow-up tests) to biennial fecal immunochemical testing from age 50 years. RESULTS: For persons age 76 years, 157 women and 108 men with a perfect screening history would need to be screened to gain 1 life-year per 1000 screened individuals. Previously unscreened women with no comorbid conditions and no history of screening could undergo an initial screening through 90 years, whereas unscreened men could undergo initial screening through 88 years, before this balance is reached. As screening adherence improved or as comorbidities increased, the optimal age to stop screening decreased to a point that, regardless of sex, individuals with severe comorbidities and a perfect screening history should stop screening at age 66 years or younger. CONCLUSIONS: Based on the harm-benefit balance, the optimal stop age for colorectal cancer screening ranges from 66 years for unhealthy individuals with a perfect screening history to 90 years for healthy individuals without prior screening. These findings can be used to assist patients and clinicians in making decisions about screening participation.
Authors: Eline H Schreuders; Arlinda Ruco; Linda Rabeneck; Robert E Schoen; Joseph J Y Sung; Graeme P Young; Ernst J Kuipers Journal: Gut Date: 2015-06-03 Impact factor: 23.059
Authors: Iris Lansdorp-Vogelaar; Roman Gulati; Angela B Mariotto; Clyde B Schechter; Tiago M de Carvalho; Amy B Knudsen; Nicolien T van Ravesteyn; Eveline A M Heijnsdijk; Chester Pabiniak; Marjolein van Ballegooijen; Carolyn M Rutter; Karen M Kuntz; Eric J Feuer; Ruth Etzioni; Harry J de Koning; Ann G Zauber; Jeanne S Mandelblatt Journal: Ann Intern Med Date: 2014-07-15 Impact factor: 25.391
Authors: Peter Catomeris; Nancy N Baxter; Sheila C Boss; Lawrence F Paszat; Linda Rabeneck; Edward Randell; Mardie L Serenity; Rinku Sutradhar; Jill Tinmouth Journal: Arch Pathol Lab Med Date: 2017-10-02 Impact factor: 5.534
Authors: Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Karina W Davidson; John W Epling; Francisco A R García; Matthew W Gillman; Diane M Harper; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Douglas K Owens; William R Phillips; Maureen G Phipps; Michael P Pignone; Albert L Siu Journal: JAMA Date: 2016-06-21 Impact factor: 56.272
Authors: Jeroen C van Rijn; Johannes B Reitsma; Jaap Stoker; Patrick M Bossuyt; Sander J van Deventer; Evelien Dekker Journal: Am J Gastroenterol Date: 2006-02 Impact factor: 10.864
Authors: P Colquhoun; H-C Chen; Jong Ik Kim; J Efron; E G Weiss; J J Nogueras; A M Vernava; S D Wexner Journal: Colorectal Dis Date: 2004-05 Impact factor: 3.788
Authors: Linda Rabeneck; Lawrence F Paszat; Robert J Hilsden; Refik Saskin; Des Leddin; Eva Grunfeld; Elaine Wai; Meredith Goldwasser; Rinku Sutradhar; Therese A Stukel Journal: Gastroenterology Date: 2008-09-13 Impact factor: 22.682
Authors: Malcolm G Dunlop; Albert Tenesa; Susan M Farrington; Stephane Ballereau; David H Brewster; Thibaud Koessler; Paul Pharoah; Clemens Schafmayer; Jochen Hampe; Henry Völzke; Jenny Chang-Claude; Michael Hoffmeister; Hermann Brenner; Susanna von Holst; Simone Picelli; Annika Lindblom; Mark A Jenkins; John L Hopper; Graham Casey; David Duggan; Polly A Newcomb; Anna Abulí; Xavier Bessa; Clara Ruiz-Ponte; Sergi Castellví-Bel; Iina Niittymäki; Sari Tuupanen; Auli Karhu; Lauri Aaltonen; Brent Zanke; Tom Hudson; Steven Gallinger; Ella Barclay; Lynn Martin; Maggie Gorman; Luis Carvajal-Carmona; Axel Walther; David Kerr; Steven Lubbe; Peter Broderick; Ian Chandler; Alan Pittman; Steven Penegar; Harry Campbell; Ian Tomlinson; Richard S Houlston Journal: Gut Date: 2012-04-05 Impact factor: 23.059
Authors: Jonathan M Downie; Moeen Riaz; Jing Xie; Minyi Lee; Andrew T Chan; Peter Gibbs; Suzanne G Orchard; Suzanne E Mahady; Robert P Sebra; Anne M Murray; Finlay Macrae; Eric Schadt; Robyn L Woods; John J McNeil; Paul Lacaze; Manish Gala Journal: Cancer Prev Res (Phila) Date: 2022-08-01
Authors: Iris Lansdorp-Vogelaar; Reinier Meester; Lucie de Jonge; Andrea Buron; Ulrike Haug; Carlo Senore Journal: Int J Cancer Date: 2021-09-06 Impact factor: 7.316